Lexaria Bioscience (LEXX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lexaria Bioscience’s DehydraTECH technology has shown promising results in a 12-week diabetes animal study by outperforming the Rybelsus® control group in body weight and blood sugar control. The DehydraTECH-liraglutide and DehydraTECH-CBD formulations were particularly effective, highlighting the potential of this innovative drug delivery platform.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.